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ABSTRACT
Receptor tyrosine kinase-like orphan receptor 1 (ROR1)
is a member of the ROR family consisting of ROR1 and
ROR2. RORs contain two distinct extracellular cysteine-
rich domains and one transmembrane domain. Within
the intracellular portion, ROR1 possesses a tyrosine
kinase domain, two serine/threonine-rich domains and a
proline-rich domain. RORs have been studied in the
context of embryonic patterning and neurogenesis
through a variety of homologs. These physiologic
functions are dichotomous based on the requirement of
the kinase domain. A growing literature has established
ROR1 as a marker for cancer, such as in CLL and other
blood malignancies. In addition, ROR1 is critically
involved in progression of a number of blood and solid
malignancies. ROR1 has been shown to inhibit apopto-
sis, potentiate EGFR signaling, and induce epithelial-
mesenchymal transition (EMT). Importantly, ROR1 is
only detectable in embryonic tissue and generally
absent in adult tissue, making the protein an ideal drug
target for cancer therapy.
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INTRODUCTION
ROR1 and ROR2 are transmembrane proteins within the
receptor tyrosine kinase (RTK) family. ROR1/2 were initially
discovered in a neuroblastoma cell line in a PCR screen for
receptor tyrosine kinases and were formerly named as
neurotrophic tyrosine kinase receptor-related (NTRKR1/2).
Human ROR1/2 have 58% amino acid identity and are clo-
sely related to MUSK and Trk family receptors (Masiakowski
and Carroll, 1992; Forrester et al., 1999). Both genes encode
proteins with a predicted molecular weight of 104 kDa, but
ROR1 has multiple N-glycosylation sites that generate post-
translationally modiﬁed ROR1 at 130 kDa. These N-glyco-
sylation sites are necessary for the trafﬁcking of ROR1 to the
membrane and in turn the function of ROR1 (Kaucká et al.,
2011). The structure of human ROR1/2 consists of an
extracellular immunoglobulin-like (Ig) domain at the amino-
terminus, followed by a cysteine-rich domain known as a
Frizzled domain (FZD), and then a Kringle domain (KRD)
into a transmembrane domain (Fig. 1A). The FZD domain is
seen in the Smoothened and Frizzled-family receptors, as
well as carboxypeptidase Z, collagen α1 XVIII, and low-
density lipoprotein receptor-related proteins (LRP) and con-
sists of 10 conserved cysteine residues and ﬁve corre-
sponding disulﬁde bonds. The FZD is thought to mediate
receptor-ligand interaction (Roszmusz et al., 2001; Forrester
et al., 2004; Mikels and Nusse, 2006). Both ROR1 and to a
greater extent in the literature, ROR2, have been shown to
bind Wnt5a, a non-canonical Wnt via the FZD (Oishi et al.,
2003; Mikels and Nusse, 2006; Fukuda et al., 2008; Paga-
noni et al., 2010). The KRD is a highly-folded, cysteine-rich
domain that mediates in protein-protein and protein-ligand
interaction in coagulation proteins, apolipoproteins, and
hepatocyte growth factor (Stephens et al., 1992; Mizuno
et al., 1994; Mathews et al., 1996). The cytoplasmic portion
of human ROR1/2 has a tyrosine kinase domain (TKD),
followed by a Serine/Threonine-rich domain (Ser/Thr), a
proline-rich domain (PRD), and a second Ser/Thr domain at
Nicholas Borcherding and David Kusner contributed equally to this
work.
© The Author(s) 2014. This article is published with open access at Springerlink.com and journal.hep.com.cn










the carboxy-terminus (Fig. 1A). The functionality of the
tyrosine kinase domain (TKD) of RORs has been debated in
the literature. Early studies showed strong autocatalytic
kinase activity for ROR2, while ROR1 possessed weak to
moderate kinase activity (Masiakowski and Carroll, 1992;
Oishi et al., 1999). More recently, ROR1 TKD was shown to
be sufﬁcient to phosphorylate c-SRC in NIH3T3 cells
(Yamaguchi et al., 2012). Conversely, another study con-
cluded that ROR1 is a pseudokinase as ROR1 did not show
any kinase activity in COS-7 cells (Gentile et al., 2011). The
ROR families are one of the most divergent within the
receptor tyrosine kinase family, containing only 21 of the 40
consensus residues in other TKDs described by Hanks and
Quinn (Hanks et al., 1988). Notably, ROR1 possesses sub-
stitutions at C482G, K614R and L634F, that should modulate
ATP binding and kinase function (Hanks et al., 1988;
Masiakowski and Carroll, 1992). The ROR family of proteins
are evolutionally conserved and share a high level of
homology between orthologs in Mus musculus, Caeno-
rhabditis elgans, Xenopus laevevis, Drosophila melnogaster,
Apylasia californica, and Gallus gallus (Wilson et al., 1993;
Forrester et al., 1999; Oishi et al., 1999; McKay et al., 2001;
Hikasa et al., 2002; Stricker et al., 2006). CAM-1 is the
singular ROR1/2 ortholog in C. elegans and shares a greater
amino acid identity to ROR1, but lacks the PRD and the
second Ser/Thr domain. DROR, a structural intermediate of
the ROR and TRK receptor family, and DRNK are the Dro-
phosilia orthologs and lack the extracellular Ig domain and
the intracellular PRD and Ser/Thr domains (Wilson et al.,
1993; Oishi et al., 1997). The conservation of RORs across
species underlies the importance of the ROR family through
a number of processes during evolution.
ROR1/2 FUNCTIONS WITHIN DEVELOPMENT
A series of studies that utilized in situ hybridization and
mutant knockout characterizations in mice have implicated
RORs in the context of skeletal, cardiorespiratory, and neu-
rological development. The expression patterns of mROR1
and mROR2 in embryos partially overlap, namely in facial
development, pharyngeal arches, nasal processes, and
much of the other derivatives of neural crest cells. In general
mROR1 is restricted to the cephalic mesenchyme and neural
crest cells, while mROR2 is expressed more broadly in both
neural and non-neural cells throughout development. Within
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Figure 1. ROR1 structure and signaling in cancer. (A) Human ROR1 consists of an immunoglobulin-like domain (IG), two
cysteine-rich domain, frizzled (FZD) and kringle domain (KRD). On the intracellular side, ROR1 possesses a tyrosine kinase domain
(TKD), two serine/threonine-rich domains (Ser/Thr), and a proline-rich domain (PRD). (B) ROR1-mediated signaling has been
reported in a number of cell lines. Wnt5a, the ligand of ROR1, increased NF-kB activation in HEK293 cells expressing ROR1. In lung
adenocarcinoma cell lines, ROR1 is able to phosphorylate c-SRC and through allosteric interaction of the FZD with EGFR magnify
the EGF-induced signaling. Alternatively, in lung carconoma and gastric carcinoma cell lines, ROR1 is phosphorylated by MET; the
silencing of ROR1 impairs cell growth. In MDA-MB-231 breast cancer cells, ROR1 expression is highly associated with EMT genes
and the silencing of ROR1 reduces the ability of MDA-MB-231 cells to form metastic foci.
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portion of the limb bud, while mROR2 expression extends
throughout the mesenchyme of the limb. Later in develop-
ment, strong expression of mROR2 is seen within the peri-
chondrium of the developing digits, while mROR1
expression is seen in the necrotic and interdigital zones (Al-
Shawi et al., 2001; Matsuda et al., 2001). The expression of
mROR2 within the subset of chondrocytes at the growth
plate and perichondrium suggests a functional role within the
development of bones with cartilaginous anlage (DeChiara
et al., 2000). The potential role of mROR2 in limb/skeletal
formation is underscored by the identiﬁcation of mutations in
hROR2. Mutations of hROR2 in the intracellular Ser/Thr
domains, PRD or nonsense mutations have been linked to
the dominant Brachydactyly Type B, characterized hypo-
plasia and/or aplasia of the hands and feet (Oldridge et al.,
2000). hROR2 mutations in the CRD, KRD, TKD, and resi-
dues immediately following TKD have also been associated
with Robinow syndrome, a recessive short-limbed dwarﬁsm
(Afzal et al., 2000; van Bokhoven et al., 2000). In late stages
of mouse development, the expression of mROR1 and
mROR2 is seen within the heart and alveoli of the lungs.
Mice with homozygous knockout of mROR2 exhibit short-
ened limbs, cyanosis, septal defects of the heart and die
within six hours of birth due to respiratory defect (Takeuchi
et al., 2000). Likewise, mROR1−/− mice have perinatally
lethal defects due to respiratory dysfunction; however, these
mice do not exhibit the pronounced heart or skeletal abnor-
malities. When researchers generated a mROR1/mROR2-
deﬁcient mouse, they found a more severe phenotype than
mROR2−/− alone, leading the authors to conclude that
mROR1/2 have a redundant, yet none overlapping function
in development (Nomi et al., 2001). In late stages of
embryonic development, the expression of mROR2 is sus-
tained in the hippocampus and caudate putamen, but
mROR1 is no longer detectable (Matsuda et al., 2001). The
temporal and localized expression of both mRORs within the
developing nervous system underscores their function in
neurogenesis.
CAM-1, the only ROR homolog in C. elegans, has been
extensively studied in neuronal cell migration, asymmetric
division, and axonal outgrowth. Mutations within the cys-
teine-rich FZD and truncating mutations before the kinase
domain result in the inhibition of axonal outgrowth, sug-
gesting a ligand-mediated function, but kinase activity may
be dispensable. However, kinase activity is necessary for
asymmetric neuronal division (Forrester et al., 1999). Addi-
tionally mutations in CAM-1 lead to defects speciﬁcally in
canal-associated neurons. CAM-1 is considered to be a
negative regulator of canonical Wnt signaling; excess EGL-
20, a canonical Wnt ligand, mirrors the neuronal phenotype
of CAM-1 mutants. The extracellular FZD is necessary and
sufﬁcient to mediate the antagonistic role for canonical Wnt
during neuronal migration (Forrester et al., 2004; Green
et al., 2007). The role of RORs in neuronal migration is seen
in others species; the Xenopus homolog xROR2 inhibits
convergent extension of the neuroectoderm via non-canon-
ical Wnt signaling (Hikasa et al., 2002). RORs have also
been indicated in synapse formation. The Aplysia ROR
homolog clusters on bag neuron cells suggesting organiza-
tion of functional sites or synapses in Aplysia californica
(McKay et al., 2001). Down regulation of ROR1 or ROR2 via
small interfering (si) RNA decreases synaptogenesis in pri-
mary mouse embryonic neuronal cultures. mROR1 and
mROR2 can form heterodimers within human embryonic
kidney (HEK) 293 cells that bind to the putative ligand
Wnt5a. Treating the primary embryonic cells with Wnt5a
increases synapse number in a dose dependent manner,
suggesting a functional role of Wnt5a-ROR1/2 in synapse
formation (Paganoni et al., 2010).
ROR1 IN CANCER
While ROR1 expression is present during normal embryonic
and fetal development, it is absent within most mature tis-
sues. A low level of ROR1 expression is seen in adipose
tissue and to a lesser degree in the pancreas, lung, and a
subset of intermediate B cells (Baskar et al., 2008; Hudecek
et al., 2010; Bicocca et al., 2012). However, the expression
of ROR1 has been seen in numerous blood and solid
malignancies. This differential expression pattern, low ROR1
expression in adult tissue and high expression in cancer
have led investigators to examine the functional advantage
conferred to cancer by ROR1 expression and to explore the
use of immune-based therapies against ROR1 for targeting
cancer cells. (Baskar et al., 2008; Barna et al., 2011; Zhang
et al., 2012a; Zhang et al., 2012b; Daneshmanesh et al.,
2013)
ROR1 in blood malignancies
Strong expression of ROR1 was initially identiﬁed in B-Cell
chronic lymphocytic leukemia (CLL). Primary CLL cells
express high levels of ROR1, but not ROR2, and this
expression was not modulated by the incubation with CD40
or IL-4 (Baskar et al., 2008). A second research group
independently identiﬁed ROR1 in CLL after ex vivo trans-
duction of CD40 ligand (CD154) and autologous infusions of
the transduced cells into advanced stage CLL patients. This
transduction reversed the characteristic immunosuppression
of CLL and resulted in the generation of antibodies against
ROR1. Furthermore, anti-ROR1 immunoglobulins were
shown to bind speciﬁcally with CLL cells, while being unre-
active towards peripheral blood mononuclear cells (PBMCs)
from CLL patients and healthy donors (Fukuda et al., 2008).
The expression of ROR1 increases through the progression
of CLL. ROR1 is not only a biomarker for CLL, but it may
serve as a potential prognostic indicator (Daneshmanesh
et al., 2013). The constitutive phosphorylation of STAT3, a
hallmark of CLL, has been shown to bind multiple sites in the
ROR1 promoter. In addition, the expression of ROR1 could
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be induced by IL-6 in a STAT3-dependent and dose-
dependent manner (Frank et al., 1997; Li et al., 2010). As
Wnt5a was shown to bind ROR1 in HEK293 cells, resulting
in NF-κB activation in a reporter construct, ROR1 may be
responsible for controlling self-expression (Fig. 1B) (Fukuda
et al., 2008). Since the discovery of the elevated expression
of ROR1 in CLL, increased levels of ROR1 have been
described in a variety of hematological malignancies,
including acute lymphocytic leukemia (ALL), non-Hodgkin
lymphomas (NHL), and myeloid malignancies (Baskar et al.,
2008; Daneshmanesh et al., 2008; Barna et al., 2011;
Daneshmanesh et al., 2013). Speciﬁcally for NHLs, when
compared to PBMCs, ROR1 mRNA and/or protein are ele-
vated in all or a subset of primary samples of mantle cell
lymphoma (MCL), marginal zone lymphoma (MZL), diffuse
large B-cell lymphoma (DLBCL), and follicular lymphoma
(Barna et al., 2011; Daneshmanesh et al., 2013). A high level
of ROR1 expression is seen in ALL patients, speciﬁcally
those with the t(1;19)(q23;p13) translocation. ROR1 is
identiﬁed to be important for the survival of ALL cells with t
(1;19)(q23;p13) translocation when using an siRNA library
for the tyrosine kinome to screen critical tyrosine kinases for
ALL pathogenesis (Bicocca et al., 2012). Examination of the
expression levels in normal and B cells at early develop-
mental stages lack ROR1 expression; however, normal B
cells in an intermediate stage of development (large/small
pre-BII and immature B cells) show relatively high levels of
ROR1 expression, which is absent within mature B cells
(Hudecek et al., 2010; Bicocca et al., 2012). Interestingly, t
(1;19) ALL cells are generally characterized as residing in
late stages of B cell differentiation, such as large/small pre-
BII. Therefore, the presence of ROR1 in t(1;19) ALL cells
may represent an arrested intermediate stage during B cell
maturation. Furthermore, these authors proposed a model
for normal B cell development, wherein ROR1 expression is
upregulated at the pre-BII large stage. This allows for the
maintenance of pro-survival signaling through MEK/ERK
activation, which would be otherwise absent during pre-BCR
internalization (Bicocca et al., 2012).
ROR1 in solid malignancies
High expression of ROR1 is also observed in a wide variety
of solid malignancies. Tissue microarray analysis showed
strong staining of ROR1 in 30% or greater of primary sam-
ples in colon, lung, and pancreatic cancers. However,
moderate staining is detected in the majority of ovarian,
lymphoma, skin, testicular, uterine, prostate, and adrenal
cancers (Zhang et al., 2012b). An RNAi-based screening in
HeLa cells identiﬁed an important role of ROR1 in regulating
apoptosis (MacKeigan et al., 2005). In lung adenocarci-
noma, NKX2-1 (TITF1) has been shown to drive ROR1
expression and the subsequent increase in ROR1 has two
distinct proposed functions, including the potentiation of EGF
ligand-induced EGFR signaling and the phosphorylation and
activation of c-Src regardless of ligand induction (Fig. 1B)
(Yamaguchi et al., 2012). As previously mentioned,
researchers have seen mild to moderate autophosphoryla-
tion of ROR1 (Masiakowski and Carroll, 1992; Oishi et al.,
1999). However, the autophosphorylation is not detected
using immunoprecipitated ectopic ROR1 in COS-7 cells,
leading the authors to conclude ROR1 is a pseudokinase. In
the same study, phosphorylated ROR1 was identiﬁed in a
number of cell lines. This phosphorylation was found to be
mediated by MET (HGFR), but not EGFR or ERBB2
(Fig. 1B). Within non-small cell lung cancer cells (NCI-
H1993), silencing of ROR1 disrupts the ability to escape
anoikis, anchorage-dependent programmed cell death, and
decreased primary tumor growth when the cells are trans-
planted into nude mice (Gentile et al., 2011). In another
study, Wnt5a, but not Wnt3a, binds to ROR1 that in turn
recruits Frizzled 4 (FZD4) through FZD4’s CRD. The tran-
sient localization allows FZD4-associated glycogen syn-
thase kinase 3β (GSK3β) to phosphorylate ROR1 on Ser/Thr
residues (Grumolato et al., 2010). Therefore, ROR1 may
serve as a common node for kinase phosphorylation and
allow for subsequent pathway activation through adaptor/
effector protein recruitment.
Segueing into breast cancer, ROR1 has been shown to
be expressed in human neoplastic breast cancer cells, while
remaining absent within stromal cells (Zhang et al., 2012a).
Furthermore, high expression of ROR1 is associated with
higher grade and more aggressive disease. ROR1, when
stimulated by recombinant Wnt5a, interacts with casein
kinase1ε (CK1ε), whose subsequent interaction with phos-
phoinositide 3-kinase (PI3K) results in the phosphorylation of
AKT and CREB (Zhang et al., 2012a). High levels of ROR1
expression in patients and cell lines are associated with
genes involved in epithelial-mesenchymal transition (EMT)
such as ZEB1 and vimentin, and inversely associate with
adherent junction proteins (Fig. 1B). Silencing of ROR1 in
triple-negative-derived cell lines reduced EMT genes,
SNAI1, SNAI2, ZEB1, and vimentin. In MDA-MB-231 cells, a
triple negative breast cancer cell line, knockdown of ROR1
by small hairpin (sh) RNA reduces in vitro cell migration and
bone and lung foci size in xenografts (Cui et al., 2013).
Although protein levels of ROR1 are low or not detectable
within the kidney of healthy individuals, ROR1 mRNA can be
detected in 81.3% of tissue samples and 94% of PBMCs
samples from renal cancer patients as determined by RT-
PCR (Rabbani et al., 2010). Furthermore, PBMCs from renal
cancer patients showed signiﬁcantly higher ROR1 expres-
sion, compared to healthy controls. While these ﬁndings
suggest that ROR1 expression is a hallmark of renal cancer,
it is important to note that the protein levels of ROR1 are not
measured in this study. The expression of ROR1 is detected
in multiple melanoma cell lines, as assessed by RT-PCR,
Western blot, and ﬂow cytometry. Silencing ROR1 in all
melanoma cell lines tested induces apoptosis (Hojjat-Fars-
angi et al., 2013). An interesting paradigm has been
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suggested in melanoma cell lines. Transcriptomic analysis of
melanoma cell lines reveals that the expression of ROR1 is
associated with a proliferative signature, but also correlates
with a non-invasive phenotype. Treatment of two poorly
invasive cell lines with recombinant Wnt5a leads to a sig-
niﬁcant decrease in ROR1 expression and overall protein
level. Interestingly, silencing ROR1 leads to an increase in
Wnt5a and ROR2 expression, supporting a more invasive
phenotype of melanoma cells. The ROR1 and ROR2
expression seems to be differentially regulated also under
hypoxic conditions that leads to decreased ROR1 expres-
sion and increased expression of ROR2 (O’Connell et al.,
2013).
ROR1, a target of immunotherapies
The discovery of ROR1 expression in CLL and other cancers
has informed a diverse array of research on immuno-based
strategies to target ROR1 (Baskar et al., 2008; Fukuda et al.,
2008). In CLL, there are an estimated 1–7 × 104 ROR1
molecules on the surface, which is 10–100 folds lower than
the conventional targets of monoclonal antibody (mAb)
therapies. Thus, the results from ex vivo analyses of mAbs
against ROR1 in CLL have been mixed. A number of studies
have reported anti-ROR1 induces ROR1 internalization
(Baskar et al., 2008; Yang et al., 2011; Baskar et al., 2012;
Daneshmanesh et al., 2013). Low levels of antibody
dependent cellular cytotoxicity (ADCC) and even lower
complement-dependent cytotoxicity (CDC) have been
reported in primary CLL samples and MCL cell lines treated
with anti-ROR1 mAbs (Yang et al., 2011; Baskar et al.,
2012). In contrast, researchers developed several mAbs
directed against the FZD and KRD of the extracellular region
that have demonstrated high levels of cytotoxicity in primary
CLL samples. These mAbs exhibit a signiﬁcantly greater
cytotoxicity than primary CLL samples treated with rituximab,
an FDA-approved mAb against CD20 (Daneshmanesh et al.,
2013). Inhibiting ROR1 by a mAb reduces metastatic foci in
lungs assessed by bioluminescence and histology with xe-
nografts of MDA-MB-231 breast cancer cells (Cui et al.,
2013). Within melanoma cell lines, treatment with anti-ROR1
mAb results in varying degrees of apoptosis, between 4%
and 54%, which is dependent upon the speciﬁc anti-ROR1
mAb and melanoma cell lines. This can be attributed partially
to the antibody-mediated complement-dependent cytotoxic-
ity (CDC) or ADCC. Importantly treatment of anti-ROR1
mAb, either directly or through CDC or ADCC, has no effect
on apoptosis in the ROR1-negative cell line T47D (Hojjat-
Farsangi et al., 2013). Research into immunotoxin therapies
has been moving forward as well. The Fv region of an anti-
ROR1 monoclonal antibody has been fused to PE38, a
modiﬁed exotoxin from Pseudomonas. The immunotoxin
exhibits similar speciﬁcity for ROR1 in MCL cell lines, but
has a higher rate of dissociation from the receptor after
internalization, which may be a limiting factor for translation
into clinical studies (Baskar et al., 2012). Another approach
also has been developed by the transduction of Tcells with a
ROR1-chimeric antigen receptor (ROR1-CAR) from healthy
individuals to CLL patients. These ROR1-CAR T cells can
recognize tumors cells and lyse primary CLL and MCL cells.
The limitation to this approach is observed in the same study.
While there is no ROR1 expression in hematopoietic pro-
genitors, ROR1 is expressed in the median stages of B-cell
maturation, in thymus-derived CD8+ and CD4+ T cells, adi-
pose tissue and adult lungs. This warrants further study of its
toxic effect for clinical usage (Hudecek et al., 2010; Bicocca
et al., 2012).
PROSPECTIVE
ROR1 is expressed in a number of malignancies with low
levels of expression in normal adult tissue. Much like the
physiological functions of ROR1, ROR1 in cancer can have
kinase activity-dependent or -independent function, which
could be a result of tissue speciﬁc expression of co-receptor
or effector proteins. The induction of apoptosis with ROR1
knockdown, EGFR signaling potentiation and ROR1-medi-
ated upregulation of EMT genes support the notion that
ROR1 plays an important role in cancer progression rather
than just a bystander. Further research is required to eluci-
date the tumor-speciﬁc mechanisms of ROR1 overexpres-
sion and the contribution of ROR1 to initiation and
progression of cancer. Furthermore, as an oncofetal protein
with absence of expression in most adult tissue, ROR1
represents an ideal druggable target for cancer therapy.
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